• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP

    6/4/25 7:00:00 AM ET
    $VIGL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $VIGL alert in real time by email

    WATERTOWN, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced an update on the Phase 2 IGNITE open-label clinical trial evaluating iluzanebart, a monoclonal antibody TREM2 agonist, for the potential treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP).

    Iluzanebart demonstrated a favorable safety, tolerability and pharmacokinetic profile across both the 20 mg/kg and 40 mg/kg dose cohorts. The Phase 2 IGNITE trial showed no beneficial effects on biomarker or clinical efficacy endpoints with treatment of iluzanebart in ALSP patients. Based upon these results, the Phase 2 long-term extension study is being discontinued in accordance with the process previously disclosed.

    "We have worked diligently over the past five years advancing our ALSP program in pursuit of a potentially effective therapy for this devastating neurodegenerative disease. Through every step, we have been deeply inspired by and profoundly grateful for the ALSP community, including patients and their families, patient advocacy groups, physicians, and trial investigators, whose courage, commitment, and partnership have been essential to driving this work forward," said Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer of Vigil. "While this is not the data outcome we hoped to see for our iluzanebart program and our patients, I am proud of what we have accomplished together. We believe our efforts and the data collected from the IGNITE clinical trial and ILLUMINATE natural history study have increased awareness and provided a deeper understanding of ALSP."

    About the Phase 2 IGNITE Clinical Trial and ILLUMINATE Natural History Study

    IGNITE was a global Phase 2, open-label proof-of-concept trial designed to evaluate iluzanebart in 20 patients with symptomatic ALSP who have a confirmed CSF1R gene mutation. The primary objective of the IGNITE trial was to evaluate the safety and tolerability of iluzanebart. Secondary outcome measures included the evaluation the effects of iluzanebart on target engagement and on MRI and NfL biomarkers of disease progression. Exploratory outcome assessments included the evaluation of clinical efficacy measures using standard cognitive, motor and functional assessments of iluzanebart in patients with ALSP. Patients enrolled in the trial received an intravenous (IV) infusion of iluzanebart at 20 mg/kg or 40 mg/kg approximately every four weeks for a treatment duration of one year. ILLUMINATE is a prospective, multi-center, natural history study of patients with ALSP and a confirmed CSF1R gene mutation. It is the first natural history study in ALSP and was designed to better understand the disease and help inform the clinical development of iluzanebart.

    About ALSP

    ALSP is a rare, inherited, autosomal dominant neurological disease with high penetrance. It is caused by a mutation to the CSF1R gene and affects an estimated 19,000 people in the United States, with similar prevalence in Europe and Japan. The disease generally presents in adults in their forties, is diagnosed through genetic testing and established clinical/radiologic criteria and is characterized by cognitive dysfunction, neuropsychiatric symptoms, and motor impairment. These symptoms typically exhibit rapid progression with a life expectancy of approximately six to seven years on average after diagnosis, causing significant patient and caregiver burden. There are currently no approved therapies for the treatment of ALSP, underscoring the high unmet need in this rare indication.

    About Vigil Neuroscience

    Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Vigil is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and their families. Vigil is developing VG-3927, a novel small molecule TREM2 agonist, to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease (AD).

    Forward-Looking Statements

    This press release includes certain disclosures that contain "forward-looking statements" of Vigil Neuroscience ("Vigil" or the "Company") that are made pursuant to the safe harbor provisions of the federal securities laws, including, without limitation, express or implied statements regarding: the potential therapeutic benefit of the Company's product candidates, including iluzanebart and VG-3927; the Phase 2 IGNITE clinical trial including the future release of data and the Company's plan to discontinue the Phase 2 IGNITE trial; beliefs about observations made analyzing clinical trial data to date, including with respect to iluzanebart . Forward-looking statements are based on Vigil's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties inherent in the development of product candidates, including the conduct of research activities and clinical trials; whether results from prior preclinical studies and clinical trials will be predictive of the results of subsequent preclinical studies and clinical trials; whether Vigil's cash resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; and the timing and content of additional regulatory information from the FDA; as well as the risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission (SEC), including Vigil's Annual Report on Form 10-K for the year ended December 31, 2024, its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, and any subsequent filings Vigil makes with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Vigil undertakes no duty to update such information except as required under applicable law. Readers should not rely upon the information in this press release as current or accurate after its publication date.

    Internet Posting of Information

    Vigil Neuroscience routinely posts information that may be important to investors in the 'Investors' section of its website at https://www.vigilneuro.com. The company encourages investors and potential investors to consult our website regularly for important information about Vigil Neuroscience.

    Investor Contact:

    Leah Gibson

    Vice President, Investor Relations & Corporate Communications

    Vigil Neuroscience, Inc.

    [email protected]

    Media Contact:

    Megan McGrath

    CTD Comms, LLC

    [email protected]



    Primary Logo

    Get the next $VIGL alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $VIGL

    DatePrice TargetRatingAnalyst
    5/28/2025$8.00Buy → Hold
    Stifel
    12/4/2024Outperform
    William Blair
    12/19/2023$13.00 → $4.00Equal-Weight → Underweight
    Morgan Stanley
    10/18/2023$23.00Mkt Outperform
    JMP Securities
    3/31/2023$15.00Buy
    Mizuho
    9/16/2022$19.00Outperform
    Wedbush
    8/29/2022$24.00Buy
    H.C. Wainwright
    2/1/2022$17.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $VIGL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Vigil Neuroscience downgraded by Stifel with a new price target

      Stifel downgraded Vigil Neuroscience from Buy to Hold and set a new price target of $8.00

      5/28/25 8:11:47 AM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • William Blair initiated coverage on Vigil Neuroscience

      William Blair initiated coverage of Vigil Neuroscience with a rating of Outperform

      12/4/24 7:51:48 AM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vigil Neuroscience downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Vigil Neuroscience from Equal-Weight to Underweight and set a new price target of $4.00 from $13.00 previously

      12/19/23 7:39:43 AM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VIGL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP

      WATERTOWN, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced an update on the Phase 2 IGNITE open-label clinical trial evaluating iluzanebart, a monoclonal antibody TREM2 agonist, for the potential treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP). Iluzanebart demonstrated a favorable safety, tolerability and pharmacokinetic profile across both the 20 mg/kg and 40 mg/kg dose cohorts. The Phase 2 IGNITE trial showed no beneficial effects on biomarker or clinical effica

      6/4/25 7:00:00 AM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi

      - Vigil's shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a non-tradeable contingent value right of $2.00 per share in cash following the first commercial sale of VG-3927 - - Acquisition expected to strengthen development path for the oral small molecule TREM2 agonist program, including VG-3927, a Phase 2-ready clinical candidate for potential treatment of Alzheimer's disease – - Companies expect transaction to close in third quarter of 2025 - WATERTOWN, Mass., May 21, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for

      5/21/25 7:30:46 PM ET
      $SNY
      $VIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Vigil Neuroscience Reports First Quarter 2025 Financial Results and Provides Recent Business Updates

      – On track to report final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALSP in Q2 2025 – – Plans to initiate Phase 2 clinical trial evaluating VG-3927 in Alzheimer's disease in Q3 2025 – WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the first quarter ending March 31, 2025, and provided updates on its recent progress. "During the quarter, we continued to make meaningful progress across our two TREM2 programs, VG-3927 and iluzanebart," said Ivana Ma

      5/7/25 7:00:00 AM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VIGL
    Leadership Updates

    Live Leadership Updates

    See more
    • Augustine Therapeutics appoints Gerhard Koenig as Chief Executive Officer as Company Prepares to Enter the Clinic

      Augustine Therapeutics appoints Gerhard Koenigas Chief Executive Officer as Company Prepares to Enter the Clinic Industry veteran Gerhard Koenig, PhD, current Executive Chairman, appointed as CEOBest-in-class highly selective HDAC6 inhibitor pioneer for disease-modifying treatment of neuromuscular, neurodegenerative and cardiometabolic diseases poised to enter the clinic LEUVEN, Belgium – February 13, 2025 – Augustine Therapeutics ("Augustine" or "the Company"), a preclinical-stage biotechnology company focused on innovative therapies for neuromuscular, neurodegenerative and cardiometabolic diseases through the inhibition of the cytosolic Histone DeACetylase 6 (HDAC6) enzyme, today announc

      2/13/25 7:00:00 AM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Augustine Therapeutics Raises EUR 17 Million in a Series A First Closing to Advance Lead Candidate Into Clinical Development in Neurological Diseases

      Proceeds will advance lead candidate AGT100216, a peripherally restricted and selective HDAC6 inhibitor, into a first-in-human clinical Phase 1/2 study Gerhard Koenig appointed as executive chairman of Augustine's Board of Directors Augustine Therapeutics, a pioneering biotech company focused on novel treatments for neurodegenerative and cardiometabolic diseases, today announced that it has raised EUR 17 million (USD 18.5 million) in the first closing of its Series A round. The financing was led by Asabys Partners, with participation from Eli Lilly and Company, and the US-based Charcot-Marie-Tooth Research Foundation. Current investors AdBio partners, V-Bio Ventures, PMV, VIB and Gem

      6/26/24 1:00:00 AM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update

      – Enrollment completed for Phase 2 trial evaluating iluzanebart in ALSP; Next data readout planned for Q3 2024 – – Phase 1 healthy volunteer trial evaluating VG-3927 for Alzheimer's disease ongoing; Interim data analysis on track for mid-2024 – WATERTOWN, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the first quarter ended March 31, 2024, and provided an update on recent progress. "During the quarter, we continued to progress iluzanebart, our monoclonal antibody, and VG-3927, our or

      5/7/24 4:05:00 PM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VIGL
    SEC Filings

    See more
    • SEC Form DEFM14A filed by Vigil Neuroscience Inc.

      DEFM14A - Vigil Neuroscience, Inc. (0001827087) (Filer)

      6/30/25 6:08:37 AM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form PREM14A filed by Vigil Neuroscience Inc.

      PREM14A - Vigil Neuroscience, Inc. (0001827087) (Filer)

      6/16/25 4:09:28 PM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SCHEDULE 13G filed by Vigil Neuroscience Inc.

      SCHEDULE 13G - Vigil Neuroscience, Inc. (0001827087) (Subject)

      6/4/25 5:24:00 PM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VIGL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Budd Haeberlein Samantha L. bought $20,520 worth of shares (12,000 units at $1.71) (SEC Form 4)

      4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)

      12/19/24 6:44:11 PM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Magovcevic-Liebisch Ivana bought $8,400 worth of shares (5,000 units at $1.68), increasing direct ownership by 2% to 222,687 units (SEC Form 4)

      4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)

      12/19/24 6:42:45 PM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Magovcevic-Liebisch Ivana bought $8,350 worth of Common Stock (5,000 units at $1.67), increasing direct ownership by 2% to 217,687 units (SEC Form 4)

      4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)

      12/18/24 5:51:48 PM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VIGL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Booth Bruce was granted 5,000 shares (SEC Form 4)

      4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)

      5/23/25 8:46:39 PM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Vitorovic Stefan was granted 5,000 shares (SEC Form 4)

      4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)

      5/23/25 8:45:31 PM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Bruhn Suzanne Louise was granted 5,000 shares (SEC Form 4)

      4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)

      5/23/25 8:44:02 PM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VIGL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Vigil Neuroscience Inc.

      SC 13G/A - Vigil Neuroscience, Inc. (0001827087) (Subject)

      11/14/24 4:19:18 PM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Vigil Neuroscience Inc.

      SC 13G/A - Vigil Neuroscience, Inc. (0001827087) (Subject)

      11/14/24 10:00:07 AM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Vigil Neuroscience Inc.

      SC 13D/A - Vigil Neuroscience, Inc. (0001827087) (Subject)

      10/9/24 6:22:58 PM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VIGL
    Financials

    Live finance-specific insights

    See more
    • Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi

      - Vigil's shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a non-tradeable contingent value right of $2.00 per share in cash following the first commercial sale of VG-3927 - - Acquisition expected to strengthen development path for the oral small molecule TREM2 agonist program, including VG-3927, a Phase 2-ready clinical candidate for potential treatment of Alzheimer's disease – - Companies expect transaction to close in third quarter of 2025 - WATERTOWN, Mass., May 21, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for

      5/21/25 7:30:46 PM ET
      $SNY
      $VIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Vigil Neuroscience Announces Interim Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating VGL101 in Healthy Volunteers Supporting Phase 2 Initiation in ALSP

      VGL101 demonstrated favorable safety, tolerability and PK profiles in single ascending dose and multiple ascending dose cohortsVGL101 achieved dose dependent, robust and durable decreases in CSF sTREM2 demonstrating proof of target engagement further validating its mechanism of action On track to initiate Phase 2 trial with a 20 mg/kg dose of VGL101 in ALSP patients this quarterCompany to host conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced interim topline r

      11/2/22 7:00:00 AM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care